Baxter Pharmaceuticals India Private Limited — Furosemide Exporter Profile
Indian Pharmaceutical Exporter · #1 for Furosemide · $7.1M export value · DGFT Verified
Baxter Pharmaceuticals India Private Limited is the #1 Indian exporter of Furosemide with $7.1M in export value and 142 verified shipments. Baxter Pharmaceuticals India Private Limited holds a 10.1% market share in Furosemide exports across 12 countries. The company exports 5 pharmaceutical products worth $19.6M across 4 therapeutic categories.
Baxter Pharmaceuticals India Private Limited — Furosemide Export Profile: Buyers & Destinations
Where Does Baxter Pharmaceuticals India Private Limited Export Furosemide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $3.1M | 70 | 65.6% |
| CANADA | $622.7K | 14 | 13.1% |
| AUSTRALIA | $290.7K | 16 | 6.1% |
| BELGIUM | $259.0K | 17 | 5.4% |
| NEW ZEALAND | $209.9K | 7 | 4.4% |
| UNITED STATES OF AMERICA | $100.0K | 2 | 2.1% |
| BULGARIA | $50.0K | 1 | 1.1% |
| ISRAEL | $33.9K | 1 | 0.7% |
| TRINIDAD AND TOBAGO | $33.5K | 2 | 0.7% |
| IRAQ | $20.4K | 1 | 0.4% |
Baxter Pharmaceuticals India Private Limited exports Furosemide to 13 countries. The largest destination is UNITED STATES accounting for 65.6% of Baxter Pharmaceuticals India Private Limited's Furosemide shipments, followed by CANADA (13.1%) and AUSTRALIA (6.1%). These destinations reflect Baxter Pharmaceuticals India Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Furosemide from Baxter Pharmaceuticals India Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BAXTER HEALTHCARE CORPORATION | UNITED STATES | $2.9M | 62 |
| STERIMAX INC | CANADA | $622.7K | 14 |
| BAXTER HEALTHCARE CORPORATION. | UNITED STATES | $300.0K | 6 |
| BAXTER DISTRIBUTION CENTRE EUROPE S | BELGIUM | $259.0K | 17 |
| BAXTER HEALTHCARE PTY. LIMITED | AUSTRALIA | $164.7K | 12 |
| BAXTER HEALTHCARE PTY LIMITED | AUSTRALIA | $126.0K | 4 |
| BAXTER HEALTHCARE LTD | NEW ZEALAND | $82.7K | 2 |
| BAXTER HEALTHCARE LTD | NEW ZEALAND | $77.2K | 4 |
| TCHAIKAPHARMA HIGH QUALITY MEDICINE | BULGARIA | $50.0K | 1 |
| BAXTER HEALTHCARE LIMITED | NEW ZEALAND | $50.0K | 1 |
Baxter Pharmaceuticals India Private Limited supplies Furosemide to 16 buyers globally. The largest buyer is BAXTER HEALTHCARE CORPORATION (UNITED STATES), followed by STERIMAX INC (CANADA) and BAXTER HEALTHCARE CORPORATION. (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Furosemide Export Value and How Much Does Baxter Pharmaceuticals India Private Limited Contribute?
India exported $43.6M worth of Furosemide through 4,657 shipments from 333 suppliers to 150 countries, serving 778 buyers globally. Baxter Pharmaceuticals India Private Limited contributes $7.1M to this total, accounting for 10.1% of India's Furosemide exports. Baxter Pharmaceuticals India Private Limited ships Furosemide to 13 countries through 16 buyers.
What Is the Average Shipment Value for Baxter Pharmaceuticals India Private Limited's Furosemide Exports?
Baxter Pharmaceuticals India Private Limited's average Furosemide shipment value is $50.0K per consignment, based on 142 shipments totaling $7.1M. The largest destination is UNITED STATES (65.6% of Baxter Pharmaceuticals India Private Limited's Furosemide exports).
How Does Baxter Pharmaceuticals India Private Limited Compare to Other Indian Furosemide Exporters?
Baxter Pharmaceuticals India Private Limited ranks #1 among 333 Indian Furosemide exporters with a 10.1% market share. The top 3 exporters are GRAVITI PHARMACEUTICALS PRIVATE LIMITED ($14.3M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($7.1M), IPCA LABORATORIES LIMITED ($3.4M). Baxter Pharmaceuticals India Private Limited processed 142 shipments to 12 destination countries.
What Furosemide Formulations Does Baxter Pharmaceuticals India Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221 | $600.0K | 12 |
| FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $450.0K | 9 |
| FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218 | $350.0K | 7 |
| FUROSEMIDE INJECTION USP10MG/ML 10ML GV | $300.0K | 6 |
| FUROSEMIDE 10 MG/ML SOLUTION FOR INJECTION 5ML GLASS AMPOULE | $281.1K | 10 |
| FUROSEMIDE INJECTION USP 10MG/ML 4ML GV CIVICA AIN03159 | $210.8K | 7 |
| FUROSEMIDE INJECTION USP 10MG/ML 4ML GV- CIVICA AIN03159NOS | $104.6K | 3 |
| FUROSEMIDE INJ USP 10MG/ML2MLGV | $100.0K | 2 |
| FUROSEMIDE INJ USP 10MG/ML4MLGV | $100.0K | 2 |
| FUROSEMIDE INJECTION USP 10MG/ML 4ML GV | $100.0K | 2 |
Baxter Pharmaceuticals India Private Limited exports 68 distinct Furosemide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221 with 12 shipments worth $600.0K.
Regulatory Requirements: Exporting Furosemide to Key Markets
What Baxter Pharmaceuticals India Private Limited must comply with to export Furosemide to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Baxter Pharmaceuticals India Private Limited Compare to Nearest Furosemide Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED | $14.3M | 1,728 | 1 | $8.3K |
| 1 | BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ★ | $7.1M | 142 | 12 | $50.0K |
| 3 | IPCA LABORATORIES LIMITED | $3.4M | 72 | 6 | $47.0K |
| 5 | AVET LIFESCIENCES PRIVATE LIMITED | $2.7M | 58 | 1 | $46.2K |
Baxter Pharmaceuticals India Private Limited ranks #1 among 333 Indian Furosemide exporters. Average shipment value of $50.0K compared to the market average of $131.0K. The closest competitors by value are GRAVITI PHARMACEUTICALS PRIVATE LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Furosemide Exports?
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD | 828 | 17.8% |
| HYDERABAD ICD (INSNF6) | 527 | 11.3% |
| SAHAR AIR | 417 | 9.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 401 | 8.6% |
| NHAVA SHEVA SEA (INNSA1) | 312 | 6.7% |
| ICD SANATHNAGAR, HYD | 162 | 3.5% |
| JNPT/ NHAVA SHEVA SEA | 137 | 2.9% |
| HYDERABAD AIR | 129 | 2.8% |
Geopolitical & Trade Policy Impact on Baxter Pharmaceuticals India Private Limited's Furosemide Exports
BPIPL's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for Indian exporters. Such challenges necessitate strategic logistics planning to maintain supply chain efficiency.
Conversely, the India-European Union Free Trade Agreement (FTA), signed in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development offers BPIPL enhanced access to European markets, potentially boosting export volumes and revenues. (en.wikipedia.org)
Additionally, the U.S. FDA's warning letter to BPIPL in July 2023 underscores the importance of stringent quality compliance. Addressing such regulatory concerns is crucial for maintaining market access and reputation. (fda.gov)
Baxter Pharmaceuticals India Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for BPIPL. The FDA's 2023 warning letter highlighted significant violations of Current Good Manufacturing Practice (CGMP) regulations at BPIPL's Ahmedabad facility. Proactive measures to rectify these issues are essential to ensure continued market access and uphold the company's reputation. (fda.gov)
Furthermore, the EU's Falsified Medicines Directive mandates rigorous tracking and verification of pharmaceutical products. BPIPL must align its operations with these requirements to capitalize on the opportunities presented by the India-EU FTA.
About Baxter Pharmaceuticals India Private Limited
Baxter Pharmaceuticals India Private Limited exports 5 products worth $19.6M. Beyond Furosemide, top products include Ondansetron, Metoclopramide, Tobramycin, Imipenem. View the complete Baxter Pharmaceuticals India Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Furosemide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Furosemide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Baxter Pharmaceuticals India Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 142 individual customs records matching Baxter Pharmaceuticals India Private Limited exporting Furosemide, covering 68 formulations to 13 countries via 16 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 150+ countries, 778+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Furosemide Export Data from Baxter Pharmaceuticals India Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Baxter Pharmaceuticals India Private Limited's Furosemide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Baxter Pharmaceuticals India Private Limited
Full Company Profile →
5 products · $19.6M total trade · 4 categories
Furosemide Stats
Company Overview
Top Products by Baxter Pharmaceuticals India Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Baxter Pharmaceuticals India Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Furosemide. For current shipment-level data, contact TransData Nexus.